FDA Lawfully Denied Exclusivity For Namenda Generic: Judge
The U.S. Food and Drug Administration acted lawfully when it denied lucrative exclusivity for a generic version of dementia drug Namenda XR, a D.C. federal judge ruled in an opinion released...To view the full article, register now.
Already a subscriber? Click here to view full article